Welcome to the e-CCO Library!

DOP070: The relationship between vedolizumab drug concentrations at or before week 6 and remission at week 14 in ulcerative colitis patients from GEMINI 1
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

X. Roblin*1, M.T. Osterman2, S. Glover3, U. Navaneethan4, M. A. Popa5, T. Wyant6, A. James7, K. Lasch5, M. Rosario6

Created: Friday, 22 February 2019, 9:49 AM
DOP071: Comparison of endoscopic responses to adalimumab monotherapy and combination therapy with azathioprine in patients with Crohn's disease: a sub-analysis of DIAMOND trial
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Watanabe K.*1, Matsumoto T.2, Motoya S.3, Hisamatsu T.4, Nakase H.5, Yoshimura N.6, Ishida T.7, Kato S.8, Nakagawa T.9, Nagahori M.10, Esaki M.11, Matsui T.12, Naito Y.13, Kanai T.14, Suzuki Y.15, Nojima M.16, Watanabe M.10, Hibi T.17

Created: Wednesday, 20 February 2019, 10:36 AM
DOP071: Tight control with adalimumab-based treatment is associated with improved quality of life outcomes in patients with moderate to severely active Crohn’s disease: data from CALM
Year: 2018
Source: ECCO '18 Vienna
Authors:

R. Panaccione1*, J.-F. Colombel2, P. Bossuyt3, F. Baert4, T. Vanasek5, A. Danalioglu6, G. Novacek7, A. Armuzzi8, W. Reinisch7, E. Neimark9, J. Petersson9, A.M. Robinson9, R.B. Thakkar9, N. Chen9, M. Skup9, W.-J. Lee9, G. D’Haens10

Created: Thursday, 21 February 2019, 9:14 AM
DOP071: Tofacitinib plasma concentration monitoring is not needed for optimisation of induction therapy in moderate-to-severe ulcerative colitis: results of pooled exposure-response analyses of Phase 3 induction studies
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

A. Mukherjee1, S. Tsuchiwata2, C. Deng3, C. Vong4, R. Xie3, S.W. Martin4, D. Yu5, D. Woodworth5, W. Niezychowski5, C. Su*5

Created: Friday, 22 February 2019, 9:49 AM
DOP072: Achieving biochemical remission with adalimumab therapy using therapeutic drug monitoring: Results of a large prospective Crohn’s disease cohort
Year: 2018
Source: ECCO '18 Vienna
Authors:

N. Plevris, P. Jenkinson, C.S. Chuah, M. Lyons, R. Hall, G. Jones, E. Watson, I. Arnott, C. Lees

Created: Thursday, 21 February 2019, 9:14 AM
DOP072: Assessment of the Ulcerative Colitis Endoscopic Index of Severity (UCEIS) using central video review of colonoscopies in paediatric patients with ulcerative colitis: data from the Canadian Children IBD Network
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Carman N.*1, Huynh H.2, Mouzaki M.3, Crowley E.3, Walsh C.M.3, Ricciuto A.3, Walters T.D.3, Church P.C.3

Created: Wednesday, 20 February 2019, 10:36 AM
DOP072: Association of ustekinumab trough concentrations with clinical, biochemical, and endoscopic outcomes
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

R. Battat1, U. Kopylov*2, T. Bessissow1, A. Bitton1, A. Cohen3, M. Martel1, E. G. Seidman4, W. Afif4

Created: Friday, 22 February 2019, 9:49 AM
DOP073: Incidental diagnosis of inflammatory bowel disease through bowel cancer screening: a 7-year experienceU. Nosegbe*1, J. A. Scott1, R. O. Butcher1, 2, A. M. Abbasi1, R. C. Prudham1, R. George1, J. Limdi1, 2
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

1The Pennine Acute Hospitals NHS Trust, Manchester, United Kingdom, 2University of Manchester, Institute of Inflammation and Repair, Manchester Academic Health Sciences Centre, Manchester, United Kingdom

Created: Friday, 22 February 2019, 9:49 AM
DOP073: Results of the sixth ECCO Scientific Workshop: The pathogenesis of inflammatory extraintestinal manifestations of inflammatory bowel disease: implications for research, diagnosis, and therapy
Year: 2018
Source: ECCO '18 Vienna
Authors:

C.R.H. Hedin1*, S.R. Vavricka2, A.J. Stagg3, A. Schoepfer4, T. Raine5, L. Puig6, U. Pleyer7, A. Navarini8, A.E. van der Meulen - de Jong9, J. Maul10, K.H. Katsanos11, A. Kagramanova12, T. Greuter13,14, Y. Gonzalez Lama15, F.A. van Gaalen16, P. Ellul17, J. Burisch18, D. Bettenworth19, M. Becker20, G. Bamias21, F. Rieder22

Created: Thursday, 21 February 2019, 9:14 AM
DOP073: Submucosal injection of the oligonucleotide STNM01 is able to induce clinical remission, mucosal healing and histological response in left-sided ulcerative colitis patients with moderate-to-severe disease
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Atreya R.*1, Kühbacher T.2,3, Waldner M.J.1, Hirschmann S.1, Drvarov O.2, Abu Hashem R.2, Maaser C.4, Kucharzik T.4, Dinter J.5, Schramm C.5, Mertens J.5, Holler B.6, Mössner J.6, Suzuki K.7, Yokoyama J.7, Terai S.7, Yoneyama H.8, Asakura H.7, Hibi T.9, Neurath M.F.1

Created: Wednesday, 20 February 2019, 10:36 AM
DOP074: IL-33 promotes gut mucosal wound healing by inducing miRNA-320 to stimulate epithelial restitution and repair
Year: 2018
Source: ECCO '18 Vienna
Authors:

L.R. Lopetuso1,2*, C. De Salvo2, L. Di Martino2, N. Rana2, W. Goodman2, F. Scaldaferri1, A. Armuzzi1, A. Gasbarrini1, T.T. Pizarro2

Created: Thursday, 21 February 2019, 9:14 AM
DOP074: Incidence and prediction of fistula formation in England
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

K. Sahnan*1, A. Askari1, S. Adegbola*1, P. Tozer1, R. Phillips1, A. Hart2, O. Faiz1

Created: Friday, 22 February 2019, 9:49 AM
DOP074: Pharmacokinetics and exposure-response of tofacitinib in a Phase 3 maintenance study in ulcerative colitis patients
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Mukherjee A.*1, D'Haens G.R.2, Sandborn W.J.3, Tsuchiwata S.4, Vong C.5, Deng C.6, Xie R.6, Hazra A.1, Martin S.W.5, Friedman G.7, Niezychowski W.7, Su C.7

Created: Wednesday, 20 February 2019, 10:36 AM
DOP075: Colonic gamma delta t-cells respond innately to NKG2D ligands and are grossly dysregulated in active inflammatory bowel disease
Year: 2018
Source: ECCO '18 Vienna
Authors:

R.J. Dart1,2,3*, P. Vantourout1,2, A. Laing1,2, J. Digby-Bell3, N. Powell3,4, P. Irving3, A. Hayday1,2

Created: Thursday, 21 February 2019, 9:14 AM
DOP075: Efficacy of filgotinib, a selective JAK1 inhibitor, is independent of prior anti-TNF exposure: subgroup analysis of the phase 2 FITZROY study in moderate-to-severe Crohn's disease
Year: 2017
Source: ECCO '17 Barcelona
Authors:

D'Haens G.1, Schreiber S.2, Petryka R.3, Kuehbacher T.4, Hebuterne X.5, Roblin X.6, Klopocka M.7, Goldis A.8, Wisniewska-Jarosinska M.9, Baranovsky A.10, Sike R.11, Stoyanova K.12, Meuleners L.13, Tasset C.13, Van der Aa A.13, Harrison P.13, Vermeire S.*14

Created: Wednesday, 20 February 2019, 10:36 AM
DOP075: Looking beyond symptoms and disease activity to define disease severity in inflammatory bowel disease: results of an IOIBD specialist panel
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

C. Siegel1, C. Whitman2, B. Spiegel2, B. Feagan3, B. Sands4, E. Loftus5, R. Panaccione6, G. D’Haens7, C. Bernstein8, R. Gearry9, S. Ng10, G. Mantzaris11, B. Sartor12, M. Silverberg13, R. Riddell13, I. Koutroubakis14, C. O’Morain15, P. Lakatos16, D. McGovern2, J. Halfvarson17, W. Reinisch18, G. Rogler19, W. Kruis20, C. Tysk17, S. Schreiber21, S. Danese22, W. Sandborn23, A. Griffiths24, B. Moum25, C. Gasche26, F. Pallone27, S. Travis28, J. Panes29, J.-F. Colombel4, S. Hanauer30, L. Peyrin-Biroulet*31

Created: Friday, 22 February 2019, 9:49 AM
DOP076: A Danish cross-sectional study: autoimmune and chronic inflammatory disorders associated with ulcerative colitis.
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

M. Halling1, T. Knudsen2, J. Kjeldsen1, J. Nielsen3, L. Koch Hansen*4

Created: Friday, 22 February 2019, 9:49 AM
DOP076: A phase 2B, multicenter, randomized, placebo-controlled dose-ranging trial of peficitinab, an oral JAK inhibitor, in patients with moderately to severely active ulcerative colitis
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Sands B.*1, Sandborn W.2, Feagan B.G.3, Lichtenstein G.4, Zhang H.5, Szapary P.5, Panes J.6, Vermeire S.7, O'Brien C.5, Dewey J.5, Yang Z.5, Johanns J.5, Strauss R.5, Marano C.5

Created: Wednesday, 20 February 2019, 10:36 AM
DOP076: IL-3 drives IL-10-secreting Tr1 cells to counteract experimental colitis
Year: 2018
Source: ECCO '18 Vienna
Authors:

S. Zundler*, M. Spocinska, V. Popp, E. Becker, R. Atreya, C. Neufert, I. Atreya, B. Weigmann, M.F. Neurath

Created: Thursday, 21 February 2019, 9:14 AM
DOP077: Deep immunophenotyping reveals a role for Mucosal Associated Invariant T (MAIT) cells in the response to anti-TNF treatment in Crohn’s disease
Year: 2018
Source: ECCO '18 Vienna
Authors:

M. Walshe*, L.A. Elliott, D. Danso-Abeam, G. Cullen, J. Sheridan, H. Mulcahy, E. Ryan, G. Doherty

Created: Thursday, 21 February 2019, 9:14 AM